Zhou Hui, Liu Yanglin, Xiao Ling, Hu Zhengmao, Xia Kun
The State Key Laboratory of Medical Genetics, School of Life Sciences, Central South UniversityChangsha, HunanP.R. China.
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityChangsha, HunanP.R. China.
Oncol Res. 2017 Jan 2;25(1):147-154. doi: 10.3727/096504016X14732772150505.
MicroRNA-27b (miR-27b) was recently found to be significantly downregulated in different human cancers. However, evidence of the function of miR-27b in non-small cell lung cancer (NSCLC) remains limited. In this study, we aimed to investigate novel miR-27b-mediated targets or signaling pathways associated with the tumorigenesis and metastasis of NSCLC. Real-time (RT) PCR was performed to examine miR-27b expression in NSCLC specimens. MTT assay, wound-healing assay, and Transwell assay were used to determine cell proliferation, migration, and invasion. Our data indicated that the miR-27b levels were significantly decreased in NSCLC specimens and cell lines (SK-MES-1, H358, H460, A549, and H1229) when compared to matched normal adjacent tissues and normal human lung epithelial cell lines, respectively. Restoration of miR-27b significantly inhibited the proliferation, migration, and invasion of A549 cells. We then conducted in silico analysis and luciferase reporter gene assay and identified MET, a receptor tyrosine kinase, as a direct target of miR-27b in NSCLC cells. Moreover, overexpression of MET rescued the suppressive effect of miR-27b on the proliferation, migration, and invasion of A549 cells, suggesting that MET acts as a downstream effecter of miR-27b in NSCLC cells. In summary, our study identified a novel miR-27b/MET signaling pathway involved in the cell proliferation, migration, and invasion of NSCLC, and identification of miR-27b-mediated novel signaling pathways may help reveal the molecular mechanism underlying the development and malignant progression of this disease.
最近发现,微小RNA-27b(miR-27b)在不同的人类癌症中显著下调。然而,miR-27b在非小细胞肺癌(NSCLC)中的功能证据仍然有限。在本研究中,我们旨在研究与NSCLC的肿瘤发生和转移相关的新型miR-27b介导的靶点或信号通路。采用实时(RT)PCR检测NSCLC标本中miR-27b的表达。采用MTT法、伤口愈合试验和Transwell试验来确定细胞的增殖、迁移和侵袭能力。我们的数据表明,与匹配的正常相邻组织和正常人类肺上皮细胞系相比,NSCLC标本和细胞系(SK-MES-1、H358、H460、A549和H1229)中的miR-27b水平显著降低。miR-27b的恢复显著抑制了A549细胞的增殖、迁移和侵袭。然后,我们进行了计算机分析和荧光素酶报告基因试验,并确定受体酪氨酸激酶MET是NSCLC细胞中miR-27b的直接靶点。此外,MET的过表达挽救了miR-27b对A549细胞增殖、迁移和侵袭的抑制作用,表明MET在NSCLC细胞中作为miR-27b的下游效应器发挥作用。总之,我们的研究确定了一条参与NSCLC细胞增殖、迁移和侵袭的新型miR-27b/MET信号通路,miR-27b介导的新型信号通路的鉴定可能有助于揭示该疾病发生发展和恶性进展的分子机制。